# Clinical Pharmacokinetics of clarithromycin

## Study Identification
- Title: Clinical Pharmacokinetics of Clarithromycin
- Author: Keith A. Rodvold
- Source: Clinical Pharmacokinetics 1999 Nov; 37(5): 385-398
- Setting: Colleges of Pharmacy and Medicine, University of Illinois at Chicago

## Antibiotic Classification
- Class: Macrolide antibiotic
- Chemical Structure: 14-membered ring macrolide
- Key Modification: Methylation of hydroxyl group at position 6 on lactone ring
- Active Metabolite: 14-hydroxyclarithromycin

## Research Objectives
1. Review pharmacokinetic properties of oral clarithromycin
2. Analyze drug interactions and their clinical significance
3. Evaluate special population considerations
4. Assess pharmacodynamic relationships

## Key Findings Summary

### Pharmacokinetic Advantages over Erythromycin:
1. Increased oral bioavailability (52-55%)
2. Enhanced plasma concentrations
   - 250mg dose: Cmax 1.01-1.52 mg/L
   - 500mg dose: Cmax 2.41-2.85 mg/L
3. Longer elimination half-life (3.3-4.9 hours)
4. Superior tissue penetration
   - 3-30 fold higher concentrations in respiratory tissues
   - 102-103 times higher in alveolar macrophages

### Clinical Parameters:
1. Primary Metabolism: CYP3A isozymes
2. Total Body Clearance: 29.2-58.1 L/h
3. Renal Clearance: 6.7-12.8 L/h
4. Protein Binding: 42-72%

# PHARMACOKINETIC ANALYSIS 

## Absorption Characteristics

### Oral Tablet Form (Adults):
1. Single Dose (250mg):
   - Cmax: 0.78-0.94 mg/L
   - Tmax: 1.8-2.8 hours

2. Multiple Dose (250mg):
   - Cmax: 1.01-1.52 mg/L
   - Trough concentrations: 0.19-0.28 mg/L

3. Single Dose (500mg):
   - Cmax: 1.65-2.12 mg/L
   - Enhanced bioavailability with food (24% increase)

4. Multiple Dose (500mg):
   - Cmax: 2.41-2.85 mg/L
   - Trough concentrations: 0.73-1.27 mg/L

### Active Metabolite (14-hydroxyclarithromycin):
- 250mg dose: Cmax 0.46-0.65 mg/L
- 500mg dose: Cmax 0.78-1.0 mg/L
- Steady-state trough levels:
  * 250mg: 0.20-0.25 mg/L
  * 500mg: 0.32-0.65 mg/L

## Distribution Characteristics

### Volume of Distribution
- Mean apparent volume (Vβ/F): 191-306L
- Demonstrates extensive tissue distribution
- Protein binding: 42-72%
- α1-acid glycoprotein: significant contributor to protein binding

### Tissue Distribution Patterns
1. Respiratory Tract Penetration:
   - Epithelial lining fluid: 3-30x plasma concentrations
   - Sputum: Significant penetration
   - Lung tissue: Enhanced distribution
   - Middle ear fluid: Therapeutic levels achieved

2. Cellular Penetration:
   - Neutrophils: Rapid accumulation
   - Alveolar macrophages: 102-103x plasma concentrations
   - Demonstrates significant intracellular accumulation

3. Distribution Ratios (Tissue:Plasma):
   ```
   Tissue                    Ratio
   Epithelial lining fluid   3-30:1
   Alveolar macrophages      100-1000:1
   Sputum                    Significant elevation
   Tonsils                   Enhanced penetration
   Nasal mucosa             Enhanced penetration
   ```

## Metabolism Patterns

### Primary Metabolic Pathways
1. Hepatic Metabolism:
   - Major pathway: CYP3A isozymes
   - 8 identified metabolites
   - Unique 14-hydroxylation pattern

2. Principal Metabolic Routes:
   - Hydroxylation (primary)
   - Oxidative N-demethylation (primary)
   - Cladinose sugar hydrolysis (minor)

3. Active Metabolite Formation:
   - 14-hydroxy-R-clarithromycin
   - Highest concentration in plasma and urine
   - Contributes to antimicrobial activity

## Elimination Parameters

### Excretion Pattern (250mg single dose)
1. Urinary Excretion:
   - Parent drug: 18.4%
   - 14-hydroxyclarithromycin: 13.7%

2. Fecal Excretion:
   - Parent drug: 4.4%
   - 14-hydroxyclarithromycin: 6.0%

### Clearance Values
1. Total Body Clearance:
   - Range: 29.16-41.34 L/h (250mg dose)
   - Dose-dependent reduction at higher doses

2. Renal Clearance:
   - Range: 6.66-12.78 L/h
   - Influenced by protein binding

### Half-life Values
1. Parent Compound:
   - 250mg dose: 3.3-4.0 hours
   - 500mg dose: 4.5-4.9 hours
   - Demonstrates dose-dependent increase

2. 14-hydroxyclarithromycin:
   - 250mg dose: 4.6-6.8 hours
   - 500mg dose: 6.9-8.7 hours

### Dose-Dependent Kinetics
1. Nonlinear Elimination:
   - Saturable metabolism
   - Dose-dependent clearance reduction
   - Increased half-life with higher doses

2. High-Dose Effects (1200mg vs 250mg):
   - 13-fold increase in AUC
   - Prolonged t1/2β (11.27 vs 4.39h)
   - Decreased clearance (24.18 vs 66.96 L/h)

# CLINICAL IMPLICATIONS AND SPECIAL POPULATIONS

## Special Population Considerations

### 1. Renal Impairment
#### Severe Impairment (CLCR 0.6-1.74 L/h):
- Significant PK alterations after 500mg q12h:
  * Cmax: ↑ to 8.27 ± 3.13 mg/L (vs 2.47 ± 0.75 mg/L in normal function)
  * Cmin: ↑ to 6.34 ± 2.69 mg/L (vs 1.04 ± 0.46 mg/L)
  * t1/2β: ↑ to 21.6h (vs 6.7h)

#### Dosing Recommendations:
- CLCR <1.8 L/h:
  * Option 1: 500mg loading dose → 250mg q12h maintenance
  * Option 2: 250mg once daily for severe impairment

### 2. Hepatic Impairment
#### Moderate-Severe (Pugh B/C):
- Parent Drug:
  * t1/2β: ↑ to 5.0h (vs 3.3h)
  * Vβ/F: ↑ to 305 ± 211L (vs 138 ± 19L)
  * CL/F: ↑ to 42.78 ± 35.58 L/h (vs 29.16 ± 9.96 L/h)

#### Active Metabolite Impact:
- Significant decreases:
  * Cmax: 0.36 ± 0.23 mg/L (vs 0.83 ± 0.37 mg/L)
  * AUC12: 3.17 ± 2.27 mg•h/L (vs 6.10 ± 2.08 mg•h/L)
  * Metabolite/parent ratio: ↓ by ~50%

### 3. Elderly Population
#### PK Changes (65-84 years):
- Parent Drug:
  * Cmax: ↑ to 3.28 ± 0.80 mg/L (vs 2.41 ± 0.67 mg/L)
  * Cmin: ↑ to 1.69 ± 0.69 mg/L (vs 0.73 ± 0.27 mg/L)
  * CL/F: ↓ to 18 ± 5.82 L/h (vs 28.56 ± 6.72 L/h)

## Clinical Applications and Pharmacodynamics

### 1. Therapeutic Targets
- Primary PD Parameter: Time above MIC (t>MIC)
- Target Achievement:
  * 250mg q12h: Effective for MIC 0.25-0.5 mg/L
  * 500mg q12h: Effective for MIC 0.5-1.0 mg/L
- Required t>MIC: 40-60% of dosing interval

### 2. Special Considerations
- H. influenzae Treatment:
  * Consider combined parent/metabolite activity
  * Maintain 2:1 parent:metabolite ratio
  * Synergistic effects observed

### 3. Tissue-Based Considerations
- Respiratory Infections:
  * Consider elevated epithelial lining fluid concentrations
  * Account for high macrophage penetration
  * May be effective against resistant strains due to local concentrations

## Drug Interactions

### 1. CYP3A-Mediated Interactions
#### High-Risk Combinations (Contraindicated):
- Astemizole
- Cisapride
- Pimozide
- Terfenadine

#### Requiring Dose Adjustment:
- Midazolam (↓ clearance 64-86%)
- Triazolam (↑ AUC 425%)
- Carbamazepine
- Cyclosporine
- Digoxin
- Theophylline

### 2. Effect of Other Drugs on Clarithromycin
#### Enzyme Inhibitors:
- Omeprazole: ↑ concentrations
- Ritonavir:
  * ↑ AUC 77%
  * ↑ Cmin 182%
  * Inhibits 14-hydroxylation

#### Enzyme Inducers:
- Rifampicin: Marked ↓ in concentrations
- Rifabutin:
  * ↓ AUC 44%
  * ↑ metabolite AUC 57%

# STANDARDIZED PHARMACOKINETIC TABLES

## Table 1: Adult Pharmacokinetic Parameters - Oral Tablet Formulation

| Parameter | 250mg Single Dose | 250mg Multiple Dose | 500mg Single Dose | 500mg Multiple Dose |
|-----------|-------------------|---------------------|-------------------|---------------------|
| Cmax (mg/L) | 0.78-0.94 | 1.01-1.52 | 1.65-2.12 | 2.41-2.85 |
| tmax (h) | 1.8-2.1 | 2.0-2.1 | 2.0-2.8 | 2.6 |
| AUC (mg•h/L) | 4.36-5.80 | 6.44-9.29 | 12.62-15.63 | 18.87-20.48 |
| t1/2β (h) | 2.7-3.3 | 3.3-4.0 | 4.2-4.3 | 4.5-4.9 |
| Vβ/F (L) | 236 | 138-228 | 306 | 191-222 |
| CL/F (L/h) | 58.1 | 29.2-41.3 | 42.1 | 26.2-28.8 |
| CLR (L/h) | NR | 6.66-12.8 | NR | 6.84-10.1 |

## Table 2: 14-Hydroxyclarithromycin Parameters

| Parameter | 250mg Single Dose | 250mg Multiple Dose | 500mg Single Dose | 500mg Multiple Dose |
|-----------|-------------------|---------------------|-------------------|---------------------|
| Cmax (mg/L) | 0.46-0.65 | 0.49-0.83 | 0.78-1.00 | 0.66-0.88 |
| tmax (h) | 2.2-2.3 | 2.5-2.9 | 1.9-2.3 | 2.5-2.6 |
| AUC (mg•h/L) | 4.59-4.97 | 4.02-6.10 | 9.45-11.18 | 6.00-7.37 |
| t1/2β (h) | 4.1-6.2 | 4.6-6.75 | 5.5-7.1 | 6.9-8.7 |
| CLR (L/h) | NR | 6.24-7.80 | NR | 8.04-8.40 |

## Table 3: Special Population Comparisons - Multiple 500mg Doses

| Parameter | Normal Function | Severe Renal Impairment | Hepatic Impairment | Elderly |
|-----------|----------------|------------------------|-------------------|---------|
| Cmax (mg/L) | 2.47 ± 0.75 | 8.27 ± 3.13 | ↓ | 3.28 ± 0.80 |
| Cmin (mg/L) | 1.04 ± 0.46 | 6.34 ± 2.69 | ↔ | 1.69 ± 0.69 |
| t1/2β (h) | 6.7 | 21.6 | 5.0 | NR |
| CL/F (L/h) | 28.56 ± 6.72 | ↓↓ | 42.78 ± 35.58 | 18.0 ± 5.82 |
| CLR (L/h) | 10.08 ± 2.1 | ↓↓ | 10.2 ± 4.14 | 5.04 ± 1.86 |

## Table 4: Tissue Distribution Ratios

| Tissue/Fluid | Concentration Ratio (vs Plasma) | Time Point |
|--------------|--------------------------------|------------|
| Epithelial Lining Fluid | 3-30x | Multiple dose steady state |
| Alveolar Macrophages | 102-103x | Multiple dose steady state |
| Neutrophils | Significant accumulation | Variable |
| Sputum | 3-30x | Multiple dose steady state |
| Middle Ear Fluid | Enhanced penetration | Variable |

## Table 5: Major Drug Interactions

| Interacting Drug | Effect on Clarithromycin | Effect on Other Drug | Clinical Recommendation |
|------------------|-------------------------|---------------------|------------------------|
| Ritonavir | ↑AUC 77%, ↑Cmin 182% | NA | Monitor, potential dose reduction |
| Rifampicin | ↓↓ Concentrations | NA | Avoid combination |
| Omeprazole | ↑AUC 15%, ↑Cmin 27% | ↑AUC 89% | No adjustment needed |
| Midazolam | NA | ↓CL 64-86% | Reduce midazolam dose |
| Triazolam | NA | ↑AUC 425% | Avoid combination |

Key:
- ↑: Increase
- ↓: Decrease
- ↓↓: Marked decrease
- ↔: No significant change
- NA: Not applicable
- NR: Not reported

Notes:
1. All values represent means or ranges from multiple studies
2. AUC values are normalized to respective dosing intervals
3. Variability data provided where available in source document
4. Tissue concentrations are approximate ratios from steady-state data
5. Drug interaction data based on multiple-dose studies

# APPENDICES

## Appendix A: Terminology Reference

### Primary PK Parameters
| Term | Definition | Units | Formula (if applicable) |
|------|------------|-------|------------------------|
| Cmax | Maximum plasma concentration | mg/L | Directly measured |
| tmax | Time to maximum concentration | h | Directly measured |
| AUC | Area under concentration-time curve | mg•h/L | Trapezoidal method |
| t1/2β | Terminal elimination half-life | h | 0.693/β |
| Vβ/F | Apparent volume of distribution | L | Dose/(β•AUC) |
| CL/F | Total body clearance | L/h | Dose/AUC |
| CLR | Renal clearance | L/h | Ae/AUC |
| F | Bioavailability | % | (AUCoral/AUCiv)•100 |

### Secondary Parameters
| Term | Definition | Description |
|------|------------|-------------|
| Cmin | Minimum plasma concentration | Trough level before next dose |
| Css | Steady-state concentration | Average concentration at equilibrium |
| ka | Absorption rate constant | First-order absorption rate |
| β | Terminal elimination rate constant | Slope of terminal elimination phase |
| Ae | Amount excreted in urine | Cumulative urinary excretion |

### Clinical Terms
| Abbreviation | Full Term | Context |
|--------------|-----------|----------|
| CLCR | Creatinine clearance | Measure of renal function |
| MIC | Minimum inhibitory concentration | Antimicrobial efficacy measure |
| t>MIC | Time above MIC | PK/PD target |
| CYP3A | Cytochrome P450 3A | Metabolic enzyme |
| AAG | α1-acid glycoprotein | Plasma binding protein |

## Appendix B: Statistical Methods

### 1. Study Design Parameters
- Design Type: Multiple pharmacokinetic studies review
- Data Collection: Both single and multiple-dose studies
- Population Sizes: Varied by study (n=12 to n=25)
- Time Points: Variable based on study design

### 2. Statistical Analysis Methods
| Analysis Type | Method Used | Software | Application |
|--------------|-------------|-----------|--------------|
| PK Analysis | Non-compartmental | Not specified | Primary parameters |
| Bioequivalence | 90% CI approach | Not specified | Formulation comparisons |
| Population Comparison | ANOVA/t-tests | Not specified | Special populations |
| Variability Assessment | CV% calculation | Not specified | Parameter variation |

### 3. Validation Methods
- Internal Consistency: Multiple study comparison
- Cross-Validation: Between-study parameter comparison
- Method Validation: Both microbiological and HPLC assays

## Appendix C: Computational Parameters

### 1. Bioanalytical Methods
| Method | Lower Limit | Upper Limit | CV% |
|--------|-------------|-------------|------|
| HPLC | Not specified | Not specified | NR |
| Microbiological | Not specified | Not specified | NR |

### 2. PK Calculations
```
AUC Calculation:
- Trapezoidal method for AUC0-t
- Extrapolation to infinity using Clast/β
- Terminal phase defined by ≥3 points

Half-life Calculation:
t1/2β = 0.693/β
where β = terminal elimination rate constant

Clearance Calculation:
CL/F = Dose/AUC0-∞
CLR = Ae/AUC0-t

Volume of Distribution:
Vβ/F = Dose/(β•AUC0-∞)
```

### 3. Drug-Drug Interaction Assessment
- Magnitude Classification:
  * Mild: <50% change
  * Moderate: 50-100% change
  * Strong: >100% change
- Clinical Significance Threshold:
  * AUC ratio >1.25 or <0.8
  * Cmax ratio >1.33 or <0.67

### 4. Special Population Adjustments
```
Renal Function:
CLCR Categories:
- Normal: >4.2 L/h
- Moderate Impairment: 1.8-4.2 L/h
- Severe Impairment: <1.8 L/h

Dose Adjustment Factor = CLCRpatient/CLCRnormal
```

Notes:
1. All concentrations reported to 2 decimal places
2. Time measurements reported to 1 decimal place
3. Clearance values rounded to nearest 0.1 L/h
4. Half-life values reported to 1 decimal place
5. Statistical significance set at p<0.05 unless otherwise specified